A recent study published in the Journal of Controlled Release explores innovative strategies to deliver RNA-based therapies directly to the lungs. The findings provide important impulses for the development of new treatment approaches for inflammatory and structural lung diseases.
RNA therapies—including mRNA- and siRNA-based approaches—enable the direct modulation of disease-relevant genes. While these technologies have already been successfully applied in other areas, such as vaccines, their targeted use in the lungs remains particularly challenging. This is due in part to the complex structure of lung tissue and natural barriers that hinder efficient drug delivery.
The current study addresses this challenge by investigating how RNA molecules can be specifically delivered into lung cells. A particular focus is placed on inhalable dry powders as a delivery method. Researchers at the DZL site CPC-M demonstrate that RNA can be stabilized through specialized carrier systems and optimized drying processes, allowing it to be formulated as an inhalable powder and delivered directly to the airways without losing its biological function.
The results show that these approaches can improve the targeted modulation of gene activity in the lungs. This opens up new possibilities for personalized therapies, for example in chronic inflammatory lung diseases. The study highlights the growing importance of RNA-based technologies in lung research and illustrates how innovative molecular strategies can contribute to making future therapies more precise and effective.
